60例口腔鳞癌p53染色模式与TP53突变状态的相关性分析

doi:10.19438/j.cjoms.2025.03.006

中国口腔颌面外科杂志 ›› 2025, Vol. 23 ›› Issue (3): 244-252.doi: 10.19438/j.cjoms.2025.03.006

60例口腔鳞癌p53染色模式与TP53突变状态的相关性分析

刘瑜^1,*, 缪可言^1,*, 胡宇华², 吴越¹, 冯冠英¹, 夏荣辉^2#, 杨溪^1#

1.上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,2.口腔病理科,上海交通大学口腔医学院,国家口腔医学中心,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海市口腔医学研究所,上海 200011

收稿日期:2025-02-06 修回日期:2025-02-27 出版日期:2025-05-20 发布日期:2025-06-05
通讯作者: 夏荣辉,E-mail: xrh335@163.com;杨溪,E-mail: yangxi16@163.com。^#共同通信作者
作者简介:刘瑜（1998-）,女,在读硕士研究生,E-mail: lscrly6389@sjtu.edu.cn;缪可言（2000-）,女,在读硕士研究生,E-mail: miaokeyan@sjtu.edu.cn。^*并列第一作者
基金资助:
国家自然科学基金（82072980,82272831）

Correlation between p53 staining and TP53 mutation status in 60 patients with oral squamous cell carcinoma

Liu Yu¹, Miao Keyan¹, Hu Yuhua², Wu Yue¹, Feng Guanying¹, Xia Ronghui², Yang Xi¹

1. Department of Oromaxillofacial Head and Neck Oncology, 2. Department of Oral Pathology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology; Shanghai Research Institute of Stomatology. Shanghai 200011, China

Received:2025-02-06 Revised:2025-02-27 Online:2025-05-20 Published:2025-06-05

摘要/Abstract

摘要： 目的：探讨口腔鳞状细胞癌（oral squamous cell carcinoma,OSCC）中p53染色模式与TP53突变状态之间的相关性,以及与临床病理特征之间的联系。方法：使用全外显子组测序和p53抗体（MX008 和 YN01766m）免疫组织化学染色分析60例OSCC患者的组织样本。将TP53突变状态和p53染色模式（缺失型[Null]、过表达[OE]和野生型[WT]）与临床病理特征进行比较,评估p53染色模式与TP53突变状态之间的相关性。采用GraphPad Prism 8软件对数据进行统计学分析。结果：TP53是OSCC中最常见的突变基因,该突变与较高的pTNM分期、DOI和PNI显著相关,并在公共数据库中展现出与不良预后的相关性。缺失模式检测功能失活（LOF）突变的灵敏度最高,而过表达模式可预测功能获得（GOF）突变,在患者分层方面具有临床价值。2种抗体在检测和匹配TP53突变状态方面表现相似。结论：TP53在OSCC中最常发生突变,其突变与不良临床病理特征和不良预后有关。p53染色对LOF突变敏感,有望成为GOF突变的生物标志物,为患者分层和靶向治疗提供一种经济有效的方法。

关键词: 口腔鳞状细胞癌, TP53突变, p53染色模式, 功能失活突变, 功能获得突变, 临床病理特征

Abstract: PURPOSE: This study aimed to investigate the correlation between p53 staining patterns and TP53 mutation status in oral squamous cell carcinoma(OSCC), as well as their associations with clinicopathologic features. METHODS: Tissue samples from 60 OSCC patients were analyzed using whole-exome sequencing and immunohistochemical staining with p53 antibodies (MX008 and YN01766m). TP53 mutation status and p53 staining patterns (Null, overexpression [OE], and wild type[WT]) were compared with clinicopathologic features. Correlations between p53 staining patterns and TP53 mutation status were evaluated. GraphPad Prism 8 software package was used for data analysis. RESULTS: TP53 was the most frequently mutated gene in OSCC, with mutations significantly associated with higher pTNM stage, DOI, and PNI, and correlated with poor prognosis in public datasets. The Null pattern exhibited the highest sensitivity in detecting loss-of-function (LOF) mutations, while OE pattern predicted gain-of-function (GOF) mutations and showed clinical value for patient stratification. Both antibodies had similar performance in detecting and matching TP53 mutation status. CONCLUSION: TP53 is the most common mutation in OSCC,and its mutation is associated with adverse clinicopathological features and poor prognosis. p53 staining is sensitive to LOF mutations and is expected to be a biomarker of GOF mutations, providing a cost-effective method for patient stratification and targeted therapy.

Key words: Oral squamous cell carcinoma, TP53 mutation, p53 staining pattern, LOF mutation, GOF mutation, Clinicopathologic features

中图分类号:

R739.8

刘瑜, 缪可言, 胡宇华, 吴越, 冯冠英, 夏荣辉, 杨溪. 60例口腔鳞癌p53染色模式与TP53突变状态的相关性分析[J]. 中国口腔颌面外科杂志, 2025, 23(3): 244-252.

Liu Yu, Miao Keyan, Hu Yuhua, Wu Yue, Feng Guanying, Xia Ronghui, Yang Xi. Correlation between p53 staining and TP53 mutation status in 60 patients with oral squamous cell carcinoma[J]. China J Oral Maxillofac Surg, 2025, 23(3): 244-252.

参考文献

[1] Martínez-Jiménez F, Muiños F, Sentís I, et al.A compendium of mutational cancer driver genes[J]. Nat Rev Cancer, 2020, 20(10): 555-572.
[2] Liu Y, Gu W.The complexity of p53-mediated metabolic regulation in tumor suppression[J]. Semin Cancer Biol, 2022, 85: 4-32.
[3] Zhou Y, Jin J, Ji Y, et al.TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma[J]. J Transl Med, 2023, 21(1): 872-887.
[4] Qayoom H, Haq BU, Sofi S, et al.Targeting mutant p53: a key player in breast cancer pathogenesis and beyond[J]. Cell Commun Signal, 2024, 22(1): 484-497.
[5] Wang Z, Burigotto M, Ghetti S, et al.Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival, and metastasis of a broad range of cancer cells[J]. Cancer Discov, 2024, 14(2): 362-379.
[6] Anderson SA, Bartow BB, Harada S, et al.p53 protein expression patterns associated with TP53 mutations in breast carcinoma[J]. Breast Cancer Res Treat, 2024, 207(1): 213-222.
[7] Novack R, Zhang L, Hoang LN, et al.Abnormal p53 immunohistochemical patterns shed light on the aggressiveness of oral epithelial dysplasia[J]. Mod Pathol, 2023, 36(7): 100153.
[8] Chen S, Zhou Y, Chen Y, et al.fastp: an ultra-fast all-in-one FASTQ preprocessor[J]. Bioinformatics, 2018, 34(17): i884-i890.
[9] Li H, Durbin R.Fast and accurate long-read alignment with Burrows-Wheeler transform[J]. Bioinformatics, 2010, 25(5): 1754-1760.
[10] Li H, Handsaker B, Wysoker A, et al.The sequence alignment/map format and SAMtools[J]. Bioinformatics, 2009, 25(16): 2078-2079.
[11] McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data[J]. Genome Res, 2010, 20(9): 1297-1303.
[12] Wang K, Li M, Hakonarson H.ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data[J]. Nucleic Acids Res, 2010, 38(16): e164.
[13] Cibulskis K, Lawrence MS, Carter SL, et al.Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples[J]. Nat Biotechnol, 2013, 31(3): 213-219.
[14] Boeva V, Popova T, Bleakley K, et al.Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data[J]. Bioinformatics, 2012, 28(3): 423-425.
[15] Layer RM, Chiang C, Quinlan AR, et al. LUMPY: a probabilistic framework for structural variant discovery[J]. Genome Biol, 2014, 15(6): R84.
[16] Johnson DE, Burtness B, Leemans CR, et al.Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1): 92-140.
[17] Köbel M, Piskorz AM, Lee S, et al.Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma[J]. J Pathol Clin Res, 2016, 2(4): 247-258.
[18] Hwang HJ, Nam SK, Park H, et al.Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer[J]. J Pathol Transl Med, 2020, 54(5): 378-386.
[19] Sakamoto I, Kagami K, Nozaki T, et al.p53 immunohistochemical staining and TP53 gene mutations in endometrial cancer: does null pattern correlate with prognosis?[J]. Am J Surg Pathol, 2023, 47(10): 1144-1150.
[20] Schoop I, Maleki SS, Behrens HM, et al.p53 immunostaining cannot be used to predict TP53 mutations in gastric cancer: results from a large Central European cohort[J]. Hum Pathol, 2020, 105: 53-66.
[21] Shirole NH, Pal D, Kastenhuber ER, et al.TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions[J]. Elife, 2017, 6: e25532.
[22] Jin Y, Zhao X, Song X, et al.The high expression of p53 is predictive of poor survival rather TP53 mutation in esophageal squamous cell carcinoma[J]. J Oncol, 2023, 2023: 3801526.
[23] Babamohamadi M, Babaei E, Ahmed Salih B, et al.Recent findings on the role of wild-type and mutant p53 in cancer development and therapy[J]. Front Mol Biosci, 2022, 9: 903075.
[24] Brosh R, Rotter V.When mutants gain new powers: news from the mutant p53 field[J]. Nat Rev Cancer, 2009, 9(10): 701-713.
[25] Arnold M, Soerjomataram I, Ferlay J, et al.Global incidence of oesophageal cancer by histological subtype in 2012[J]. Gut, 2015, 64(3): 381-387.
[26] Allemani C, Matsuda T, Di Carlo V, et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075.
[27] Leroy B, Ballinger ML, Baran-Marszak F, et al.Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice[J]. Cancer Res, 2017, 77(6): 1250-1260.
[28] Chien CY, Huang CC, Cheng JT, et al.The clinicopathological significance of p53 and p21 expression in squamous cell carcinoma of hypopharyngeal cancer[J]. Cancer Lett, 2003, 201(2): 217-223.
[29] Li XM, Song X, Zhao XK, et al.The alterations of cytokeratin and vimentin protein expressions in primary esophageal spindle cell carcinoma[J]. BMC Cancer, 2018, 18(1): 356-368.
[30] Yang X, Tian X, Wu K, et al.Prognostic impact of perineural invasion in early stage oral tongue squamous cell carcinoma: results from a prospective randomized trial[J]. Surg Oncol, 2018, 27(2): 123-128.

60例口腔鳞癌p53染色模式与TP53突变状态的相关性分析

Correlation between p53 staining and TP53 mutation status in 60 patients with oral squamous cell carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李红云, 段晓峰. 清道夫受体家族在口腔鳞状细胞癌免疫治疗中的研究进展[J]. 中国口腔颌面外科杂志, 2025, 23(3): 297-301.
[2]	王欣, 金城, 崔焕焕. 口腔鳞状细胞癌组织中miR-155-5p、miR-138及miR-381-3p的表达变化及临床意义[J]. 中国口腔颌面外科杂志, 2025, 23(2): 159-164.
[3]	薛俊青, 张莺, 胡宇华, 李江, 夏荣辉. 三级淋巴结构与头颈部鳞癌临床病理特征及预后的相关性分析[J]. 中国口腔颌面外科杂志, 2024, 22(6): 541-546.
[4]	孙晓梅, 段晓峰. 去泛素化酶在口腔鳞癌中的研究进展[J]. 中国口腔颌面外科杂志, 2024, 22(3): 294-299.
[5]	李锦存, 翟堃, 胡晨, 刘絮影, 马兴平, 马坚. 整合WGNCA和PPI网络鉴定口腔鳞状细胞癌的关键基因[J]. 中国口腔颌面外科杂志, 2024, 22(2): 128-136.
[6]	周鑫霞，刘敬浩，甘桂芳，陈福祥. 鞘氨醇-1-磷酸受体4在口腔鳞状细胞癌中的表达及生物学功能[J]. 中国口腔颌面外科杂志, 2024, 22(1): 10-15.
[7]	韩林孜, 周建华, 董磊, 赵璐, 袁荣涛. 肿瘤相关成纤维细胞对口腔鳞状细胞癌生物学行为影响的研究进展[J]. 中国口腔颌面外科杂志, 2024, 22(1): 84-91.
[8]	李贵忠, 李洁莹, 周凯, 孟宇翔, 王可心, 葛胜优, 宋凯, 冯元勇, 陶月琴, 展晓红, 尚伟. 淋巴结外扩展对口腔鳞癌患者TNM分期及生存预后的影响[J]. 中国口腔颌面外科杂志, 2023, 21(4): 377-383.
[9]	热孜万姑丽·亚森, 买热拍提·买明, 李晨曦, 龚忠诚. 牙龈卟啉单胞菌促进口腔鳞状细胞癌进展的作用及机制研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(2): 186-190.
[10]	兰嵘, 阮敏, 韩楠男, 王凤. 左下种植修复后发生植体周围鳞状细胞癌1例报告[J]. 中国口腔颌面外科杂志, 2023, 21(2): 203-205.
[11]	苏姿尚, 崔文丽, 张梦云, 姚志涛. 口腔鳞状细胞癌患者颈部淋巴结特征与预后的关系[J]. 中国口腔颌面外科杂志, 2023, 21(1): 41-48.
[12]	韩林孜, 房义康, 禹雯怡, 王奇民, 童磊, 邱建忠, 袁荣涛. 口腔乳头状唾液腺瘤1例临床病理分析[J]. 中国口腔颌面外科杂志, 2022, 20(1): 98-100.
[13]	陈秀敏, 刘族志, 林建能. 血浆miR-136-5p表达水平对口腔鳞状细胞癌患者预后预测的价值[J]. 中国口腔颌面外科杂志, 2020, 18(6): 526-530.
[14]	梁思源, 赵铜超, 周知航, 琚梧桐, 刘莹, 张志愿, 钟来平. 可利霉素对口腔鳞癌细胞生物学活性的影响[J]. 中国口腔颌面外科杂志, 2020, 18(4): 308-313.
[15]	王锋, 李翔, 王宇帆, 杨宏宇. 环状RNA在口腔鳞状细胞癌中的作用探讨[J]. 中国口腔颌面外科杂志, 2019, 17(6): 496-502.